Simultaneous integrated boost intensitymodulated radiotherapy (SIB-IMRT) combined with nimotuzumab for locally advanced esophageal squamous cell carcinoma (ESCC): A phase II clinical trial

To evaluate the feasibility, safety and efficacy of concurrent simultaneous integrated boost intensitymodulated radiotherapy (SIB-IMRT) combined with nimotuzumab in the treatment of locally advanced esophageal squamous cell cancer (ESCC).